The issuance of 25,500 new shares has been registered with the Norwegian Register of Business Enterprises. Following registration, the share capital of Photocure is NOK 13,471,910 divided into 26,943,820 shares, each share having a par value of NOK 0.50 and carrying one vote in the Company’s general meeting.
For further information, please contact:
CFO Erik Dahl
Tel: +47 450 55 000
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This information is subject to the disclosure requirements pursuant to sections 5-12 of the Norwegian Securities Trading Act.